FDA approves Takeda Gattex for treatment of children with short bowel syndrome over 1 year of age

In children, SBS is a chronic, life-threatening diseasePatients due to congenital or acquired disease, need surgery to remove most of the intestines, resulting in poor absorption of nutrients and moisturerecently, Takeda(http://announced that the U.SFDA(http://approved the company's Gatex (teduglutide) to expand its use to treat children with short bowel syndrome (SBS) who need intravenous infusion treatmentAbout Gattex
Gattex, adrug(http:// that simulates glucagon-like peptide-2 (GLP-2)It helps the remaining intestines absorb more nutrientspharmacological studies in adult patients have shown that Gattex improves fluid levels absorbed by the gutGattex has been approved for treatment of adult SBS patientsThe studythis approval is based on a 24-week clinicaltrial(http://The results showed that 69% of patients who received 0.05 mg/kg of Gatex treatment per day received more than 20% less ps infusionsPatients received an average 42% less PS infusion than baselineGattex reduced PS infusions by an average of three hours per day, and 12% of patients no longer needed TO receive PS